Chelsea scored FDA approval for Northera, but the launch is no sure bet

Chelsea Therapeutics' ($CHTP) antidizziness drug Northera finally came out a winner at the FDA, securing approval to fight faintness in patients with a rare disorder. But success is not guaranteed: The approval came with a daunting label and some strings attached. Report